Clinical use of phosphorylated proteins in blood serum analysed by immobilised metal ion affinity chromatography and mass spectrometry

Journal of Proteomics

Volumn 76, Issue , 2012, Pages 36-42

  Jaros, Julian A J ^a   Guest, Paul C ^a   Ramoune, Hassan ^a   Rothermundt, Matthias ^b,c   Leweke, F Markus ^d,e   Martins de Souza, Daniel ^a   Bahn, Sabine ^a,f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Evangelisches und Johanniter Klinikum Niederrhein   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Drug response monitoring; Phosphoproteome; Phosphorylation; Serum

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN B; CERULOPLASMIN; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; FIBRONECTIN; INTER ALPHA TRYPSIN INHIBITOR; PHOSPHOPROTEIN;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; FEMALE; HUMAN; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHROMATOGRAPHY, AFFINITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHOPROTEINS;

EID: 84869883685     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.02.015     Document Type: Article

References (60)

1. Zhou M., Lucas D.A., Chan K.C., Issaq H.J., et al. An investigation into the human serum "interactome". Electrophoresis 2004, 25:1289-1298.
2. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56:177-185.
3. Veenstra T.D., Conrads T.P., Hood B.L., Avellino A.M., et al. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005, 4:409-418.
4. Zhang Q., Faca V., Hanash S. Mining the plasma proteome for disease applications across seven logs of protein abundance. J Proteome Res 2011, 10:46-50.
5. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
6. Carrascal M., Gay M., Ovelleiro D., Casas V., et al. Characterization of the human plasma phosphoproteome using linear ion trap mass spectrometry and multiple search engines. J Proteome Res 2010, 9:876-884.
7. Zhou W., Ross M.M., Tessitore A., Ornstein D., et al. An initial characterization of the serum phosphoproteome. J Proteome Res 2009, 8:5523-5531.
8. Venter J.C., Adams M.D., Myers E.W., Li P.W., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
9. Hunter T. Signaling and beyond. Cell 2000, 113-127.
10. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
11. Stoothoff W.H., Johnson G.V. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005, 1739:280-297.
12. Schmidt S.R., Schweikart F., Andersson M.E. Current methods for phosphoprotein isolation and enrichment. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 849:154-162.
13. Levin Y., Jaros J.A., Schwarz E., Bahn S. Multidimensional protein fractionation of blood proteins coupled to data-independent nanoLC-MS/MS analysis. J Proteomics 2010, 73:689-695.
14. Yu Y.Q., Campuzano I., Gilar M. Enhanced nanoLC/MS analysis of phosphopeptides. Application Note 2006, Waters Corporation, Milford, USA.
15. Bateman R.H., Carruthers R., Hoyes J.B., Jones C., et al. A novel precursor ion discovery method on a hybrid quadrupole orthogonal acceleration time-of-flight (Q-TOF) mass spectrometer for studying protein phosphorylation. J Am Soc Mass Spectrom 2002, 13:792-803.
16. Li G.-Z., Vissers J.P.C., Silva J.C., Golick D., et al. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics 2009, 9:1696-1719.
17. Yang X., Levin Y., Rahmoune H., Ma D., et al. Comprehensive two-dimensional liquid chromatography mass spectrometric profiling of the rat hippocampal proteome. Proteomics 2011, 11:501-505.
18. Stelzhammer V., Rothermundt M., Guest P.C., Michael N., et al. Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy. Proteomics Clin Appl 2011, 5:644-649.
19. Krishnamurthy D., Levin Y., Harris L.W., Umrania Y., et al. Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. Proteomics 2011, 11:495-500.
20. Lu P., Vogel C., Wang R., Yao X., Marcotte E.M. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol 2007, 25:117-124.
21. Ralhan R., Masui O., Desouza L.V., Matta A., et al. Identification of proteins secreted by head and neck cancer cell lines using LC-MS/MS: strategy for discovery of candidate serological biomarkers. Proteomics 2011, 11:2363-2376.
22. Martins-de-Souza D., Guest P.C., Steeb H., Pietsch S., et al. Characterizing the proteome of the human dorsolateral prefrontal cortex by shotgun mass spectrometry. Proteomics 2011, 11:2347-2353.
23. Knight Z.A., Schilling B., Row R.H., Kenski D.M., et al. Phosphospecific proteolysis for mapping sites of protein phosphorylation. Nat Biotechnol 2003, 21:1047-1054.
24. Schlosser A., Pipkorn R., Bossemeyer D., Lehmann W.D. Analysis of protein phosphorylation by a combination of elastase digestion and neutral loss tandem mass spectrometry. Anal Chem 2001, 73:170-176.
25. Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A. Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 2007, 104:2199-2204.
26. Wilkinson J.M. Practical protein chemistry: a handbook 1986, Springer Protocols; John Wiley and Sons, New York. A. Darbre (Ed.).
27. Cagney G., Amiri S., Premawaradena T., Lindo M., Emili A. In silico proteome analysis to facilitate proteomics experiments using mass spectrometry. Proteome Sci 2003, 1:5.
28. Hunter T. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos Trans R Soc Lond B Biol Sci 1998, 353:583-605. The Croonian Lecture.
29. Hunter T., Sefton B.M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci U S A 1980, 77:1311-1315.
30. Ubersax J.A., Ferrell J.E. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 2007, 8:530-541.
31. Olsen J.V., Blagoev B., Gnad F., Macek B., et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127:635-648.
32. Oda Y., Nagasu T., Chait B.T. Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat Biotechnol 2001, 19:379-382.
33. Kalume D.E., Molina H., Pandey A. Tackling the phosphoproteome: tools and strategies. Curr Opin Chem Biol 2003, 7:64-69.
34. Zolnierowicz S., Bollen M. Protein phosphorylation and protein phosphatases. De Panne, Belgium, September 19-24, 1999. EMBO J 2000, 19:483-488.
35. Cohen P. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur J Biochem 2001, 268:5001-5010.
36. Eriksson J., Fenyö D. Protein identification in complex mixtures. J Proteome Res 2005, 4:387-393.
37. Koutroukides T.A., Guest P.C., Leweke F.M., Bailey D.M.D., et al. Characterization of the human serum depletome by label-free shotgun proteomics. J Sep Sci 2011, 34:1621-1626.
38. Björhall K., Miliotis T., Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005, 5:307-317.
39. Roche S., Tiers L., Provansal M., Seveno M., et al. Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: the more the better?. J Proteomics 2009, 72:945-951.
40. Smith M.P.W., Wood S.L., Zougman A., Ho J.T.C., et al. A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. PROTEOMICS 2011.
41. Rai A.J., Gelfand C.A., Haywood B.C., Warunek D.J., et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5:3262-3277.
42. Boyanton B.L., Blick K.E. Stability studies of twenty-four analytes in human plasma and serum. Clin Chem 2002, 48:2242-2247.
43. Hoffmann R., Vasko M., Otvos L. Serum stability of phosphopeptides. Anal Chim Acta 1997, 352:319-325.
44. McLachlin D.T., Chait B.T. Analysis of phosphorylated proteins and peptides by mass spectrometry. Curr Opin Chem Biol 2001, 5:591-602.
45. Clifton J., Huang F., Rucevic M., Cao L., et al. Protease inhibitors as possible pitfalls in proteomic analyses of complex biological samples. J Proteomics 2011, 74:935-941.
46. Herlitz J., Svensson L. The value of biochemical markers for risk stratification prior to hospital admission in acute chest pain. Acute Card Care 2008, 10:197-204.
47. Martins-de-Souza D., Guest P.C., Vanattou-Saifoudine N., Wesseling H., et al. The need for phosphoproteomic approaches in psychiatric research. J Psychiatr Res 2011, 45(10):1404-1406.
48. Jaros J.A.J., Martins-de-Souza D., Rahmoune H., Schwarz E., et al. Differential phosphorylation of serum proteins reflecting inflammatory changes in schizophrenia patients. Eur Arch Psychiatry Clin Stud 2011.
49. Baylor Breast Care Center, Baylor College of Medicine, A Randomized Multicenter Trial of Neoadjuvant Taxotere and Adriamycin/Cytoxan(AC): A Biologic Correlative Study 2002.
50. Lin K., Glenn M.A., Harris R.J., Duckworth A.D., et al. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications. Cancer Res 2006, 66:7801-7809.
51. Druker B.J., Tamura S., Buchdunger E., Ohno S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
52. Cohen P. Protein kinases-the major drug targets of the twenty-first century? Nature reviews. Drug Discov 2002, 1:309-315.
53. Desmedt C., Durbecq V., Paesmans M., Sotiriou C., et al. Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with single-agent doxorubicin or single-agent docetaxel. AACR Meeting Abstracts 2004, 263. 2004.
54. Berrada N., R.C., Delaloge S., Spielmann M., Andre F. 2009 ASCO Annual Meeting 2009, Gustave Roussy Institute, Paris, France.
55. Liu J.M., Hwang B.S., Wang L.S., Huang M.H., et al. Topoisomerase 2{alpha} plays a pivotal role in the tumor biology of advanced thymic neoplasia. AACR Meeting Abstracts 2006, 125. 2006.
56. Satow R., Shitashige M., Kanai Y., Takeshita F., et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 2010, 16:2518-2528.
57. Chang Q., Chen J., Beezhold K.J., Castranova V., et al. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer 2009, 8:64.
58. Parsels L.A., Qian Y., Tanska D.M., Gross M., et al. Assessment of Chk1 phosphorylation as a pharmacodynamic biomarker of Chk1 inhibition. Clin Cancer Res 2011.
59. Matei D., Sill M.W., Lankes H.A., Degeest K., et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol 2010, 29:69-75.
60. Sak A., Stuschke M. Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol 2010, 20:223-231.